Acrivon Therapeutics(us:ACRV)

    6.31

    -5.96%

    Updated on 2024-12-23

    Open:6.75
    Close:6.31
    High:6.75
    Low:6.24
    Pre Close:6.71
    Volume:43890.00
    Amount:284250.66
    Turnover:0.14%
    Shares:31.14M
    MarketCap:196.47M

    About

    Acrivon Therapeutics, Inc. develops drugs for clinical treatment. Its unique precision medicine platform is Acrivon Predictive Precision Proteomics (AP3). AP3 is used to generate proprietary OncoSignature companion diagnostics to identify patients who will benefit from the medicine. The company was founded by Peter Blume-Jensen and Kristina Masson in 2018 and is headquartered in Watertown, MA.
    Address:480 Arsenal Way,Suite 100

    Market Movers